Key Highlights

  • Lunai Bioworks (NASDAQ:LNAI) fell 5.45% to USD 0.26 in the pre-market snapshot of Tuesday, October 27, 2026 after disclosing that Nasdaq trading is expected to be suspended on Friday, October 30, 2026, with a stockholders' deficit of USD 9,024,946.
  • Estrella Immunopharma (NASDAQ:ESLA) fell 6.28% to USD 0.8611, with cash of USD 146,670 at June 30, 2026 and two Nasdaq deficiency notices, for the bid price and for market value, carrying deadlines in February and March 2027.
  • Valion Bio (NASDAQ:VBIO) fell 10.60% to USD 0.7510 with no dated announcement. It regained minimum bid compliance on Tuesday, September 22, 2026, but its latest quarterly filing states substantial doubt about going concern.
  • Wheeler Real Estate Investment Trust (NASDAQ:WHLR) fell 6.05% to USD 0.32 with no company-specific announcement, a quote below the USD 1.00 level that Nasdaq uses as a minimum bid price standard.

Lunai Bioworks (NASDAQ:LNAI): delisting is the stated plan

Lunai Bioworks (NASDAQ:LNAI), a company developing AI-enabled discovery platforms, preclinical cell and gene therapy programmes and biodefense tools, traded 5.45% lower. The catalyst is the company's release of Thursday, October 22, 2026, which reported a Nasdaq delisting determination. The company stated that it plans to delist voluntarily and deregister and will not request a hearing. Delisting is expected on or about Thursday, November 12, 2026. The decline appears consistent with holders reducing positions before the suspension, which is an inference from the timing.

The annual report summary for the fiscal year ended June 30, 2026 shows revenue of USD 51,992, all from one research-services customer, and a net loss of USD 3,562,479, helped by a gain of about USD 12.0 million on a bankruptcy. Operating expenses were USD 8,749,925. Cash was USD 1,713,653, the working capital deficit was USD 16,874,093 and the filing carries going concern language. Nasdaq cited a stockholders' deficit against a USD 2,500,000 minimum. No over-the-counter quotation is planned, so the company cannot assure that any trading market will exist after the suspension, and reporting may cease once deregistered.

Estrella Immunopharma (NASDAQ:ESLA): two deficiencies and almost no cash

Estrella Immunopharma (NASDAQ:ESLA), a clinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies for cancers, traded 6.28% lower. The company announced, on or about Monday, October 26, 2026, the appointment of Cynthia Pussinen as chief executive officer and chairperson, while Cheng Liu became chief scientific officer and remains president. A change of chief executive on the eve of the session may have prompted repositioning, which is an inference, and the move also appears consistent with thin liquidity.

The quarterly report of Thursday, August 13, 2026 showed a net loss of USD 2.3 million for the quarter ended June 30, 2026 and USD 4.6 million for six months. Simple arithmetic on the net loss and the cash balance of USD 146,670 shows cash covered a small fraction of one quarter of losses at the reported rate. Nasdaq notified the company on Monday, August 17, 2026 of a bid price deficiency, with a deadline of Tuesday, February 16, 2027, and on Tuesday, September 1, 2026 of a market value deficiency, with a deadline of Monday, March 1, 2027. The bull reading rests on early EB103 data, in which nine patients showed a 100% complete response rate at Month 1, and on a fifth clinical site opened on Wednesday, October 14, 2026. Required financing implies dilution.

Valion Bio (NASDAQ:VBIO): compliance regained, solvency unresolved

Valion Bio (NASDAQ:VBIO), formerly Tivic Health Systems, a biotechnology company that licenses Entolimod for acute radiation syndrome and operates a contract development and manufacturing subsidiary named Velocity Bioworks, traded 10.60% lower. No company-specific announcement dated on or just before the session accompanied the move. The decline appears consistent with thin liquidity and with a share price that has again moved below USD 1.00 after the 1-for-25 reverse split of Monday, August 31, 2026, which is an inference.

The Form 10-Q for the quarter ended June 30, 2026 shows no revenue line and a net loss of USD 7,103 thousand, or USD 2.17 per share, against USD 13,305 thousand for the six months. Cash was USD 2,108 thousand, against USD 12,645 thousand at Wednesday, December 31, 2025, and the filing states substantial doubt about going concern. Common shares outstanding rose to 22,189,739 at Thursday, August 13, 2026, before the split, as preferred stock converted and warrants were exercised. The bull reading is a first approval of Entolimod in Ukraine, which could come as early as the fourth quarter of 2026. The bear reading is that cash is small against the quarterly loss, so further equity financing appears likely, and renewed bid price non-compliance would follow dilution.

Wheeler REIT (NASDAQ:WHLR): a low quote without a notice

Wheeler Real Estate Investment Trust (NASDAQ:WHLR), a real estate investment trust, or REIT, which owns and operates retail properties, traded 6.05% lower. No company-specific announcement dated on or just before the session accompanied the move. The decline appears consistent with thin pre-market liquidity and with the volatility typical of a stock priced well below USD 1.00, where a change of a few cents is a large relative move. The most recent formal disclosure was the company's release of Thursday, August 6, 2026.

That release covered the three and six months ended June 30, 2026, and pointed readers to the Form 10-Q and supplemental data for revenue, occupancy, debt and cash, which are not reproduced here. Preferred stock ranks ahead of common stock for dividends and liquidation, so the Series D redemption programme shapes the claims ahead of common holders, since rental income must cover property costs, debt service and preferred obligations. The bear reading is debt and preferred burdens against property income, tenant concentration and refinancing risk. Any exchange notice would follow from the bid price rule, but none is described in the material reviewed.

Where Things Stand

The answer is that listing risk reaches these four names at different stages. Lunai Bioworks (NASDAQ:LNAI) is already leaving Nasdaq. Estrella Immunopharma (NASDAQ:ESLA) holds two open notices and almost no cash, and Valion Bio (NASDAQ:VBIO) has cured one deficiency but carries going concern doubt. Wheeler Real Estate Investment Trust (NASDAQ:WHLR) shows only a sub-USD 1.00 quote, with leverage as the underlying exposure.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, the Lunai suspension on Friday, October 30, 2026, the Estrella deadlines of Tuesday, February 16, 2027 and Monday, March 1, 2027, and the next monthly Series D update from Wheeler. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.